Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2191-219X
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study ; volume:10 ; number:1 ; day:17 ; month:8 ; year:2020 ; pages:1-9 ; date:12.2020
EJNMMI Research ; 10, Heft 1 (17.8.2020), 1-9, 12.2020

Creator
Stadt, E. A. van de
Yaqub, M.
Lammertsma, A. A.
Poot, A. J.
Schober, P. R.
Schuit, R. C.
Smit, E. F.
Bahce, I.
Hendrikse, N. H.
Contributor
SpringerLink (Online service)

DOI
10.1186/s13550-020-00684-4
URN
urn:nbn:de:101:1-2020100823502617096582
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Stadt, E. A. van de
  • Yaqub, M.
  • Lammertsma, A. A.
  • Poot, A. J.
  • Schober, P. R.
  • Schuit, R. C.
  • Smit, E. F.
  • Bahce, I.
  • Hendrikse, N. H.
  • SpringerLink (Online service)

Other Objects (12)

Afatinib in advanced NSCLC: a profile of its use

Afatinib in advanced NSCLC: a profile of its use

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V

Correction to: Afatinib in advanced NSCLC: a profile of its use

Correction to: Afatinib in advanced NSCLC: a profile of its use

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques

18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques

Impact of 18F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC

Impact of 18F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC

Prognostic nomogram combining 18F-FDG PET/CT radiomics and clinical data for stage III NSCLC survival prediction

Prognostic nomogram combining 18F-FDG PET/CT radiomics and clinical data for stage III NSCLC survival prediction

Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients

Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Correlation between chest DW-MRI and 18F-FDG PET/CT in newly diagnosed non-small cell lung cancer (NSCLC)

Correlation between chest DW-MRI and 18F-FDG PET/CT in newly diagnosed non-small cell lung cancer (NSCLC)

Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan

Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan

Related objects